Ibrahim Komeil
☆    

Egypt,
2019-11-18 09:03

Posting: # 20818
Views: 622
 

 Furosemide oral tablet [Regulatives / Guidelines]

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?
Activity
 Admin contact
20,642 posts in 4,327 threads, 1,436 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).
Forum time: 22:01 CEST (Europe/Vienna)

I have had my results for a long time:
but I do not yet know how I am to arrive
at them.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5